Eli Lilly's new experimental weight loss drug retatrutide yielded up to 28% weight loss, which is greater than that of ...

For many, GLP-1 drugs like Zepbound and Wegovy offered an ideal solution to diabetes and weight loss: a shot or pill that ...

A new clinical trial from Eli Lilly and Company suggests its experimental triple hormone drug, retatrutide, could become one ...

A new study shows those who took retatrutide lost a whopping 28% of their body weight after 80 weeks, similar to weight loss ...

People who got the injection, retatrutide, lost 28 percent of their body weight on average after 80 weeks, Eli Lilly said.

Lilly’s weight loss pill gained approval in April 2026, around three months after Novo Nordisk gained the same accolade for oral Wegovy.

Eli Lilly’s highly anticipated new weight loss drug, retatrutide, helped people lose up to 30% of their body weight, about 85 pounds, in a late-stage clinical trial, the drugmaker said in a news relea ...

The pharma giant is taking steps to expand its portfolio.

Lilly’s new obesity drug produced roughly 28% average weight loss in trials — big efficacy, real safety and access questions.

Side effects like nausea, vomiting, diarrhea and constipation are common soon after starting GLP-1s or increasing the drug’s dosage. A nutrient-dense diet and regular exercise a ...

Losing weight is not about finding the most extreme workout on the internet. It is about choosing movement you can repeat, ...

Mounjaro and Zepbound are two brand-name glucagon-like peptide-1 (GLP-1) medications manufactured by Eli Lilly. Although they ...